Here, Sherene Min, Vice President and Head of Global Clinical Development at ViiV Healthcare, explains how the HIV treatment landscape is changing, with moves towards long acting and self‑administered treatments.
Since the HIV epidemic began in the early 1980s, more than 85 million people have been diagnosed worldwide and about 40 million have died as a result of complications from the virus.1 Now, four decades later, 39 million people around the world are living with HIV, primarily due to advances in treatment.1 With continued innovation on the horizon in terms of prevention and treatment methods, what was once a wishful hope of ending the epidemic has become a conceivable goal.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
HIV treatment and prevention are at an inflection point after years of continuously improving the standard of care of once-daily oral medicines. Our industry is on the cusp of the next wave of medicines that will guide the coming decade of HIV care, making HIV a smaller part of people’s lives. In just the past three years, we have seen a shift of focus to longer-acting options. Future innovation will be defined by ultra-long-acting options, self‑administration and, hopefully, concrete steps toward a cure.
Reducing HIV treatment burden and stigma
Decades of pharmaceutical advances and an array of treatment and prevention options mean that many people living with HIV can expect to live longer and fuller lives. In fact, a study published in 2023 in The Lancet HIV revealed that women and men with HIV at age 40 had an average of 39 and 37 years of life left, respectively – only a few years less than that of the general population – if they started antiretroviral therapy (ART) after 2015.2
Broadly neutralising antibodies (bNAbs), capsid inhibitors and maturation inhibitors all might play a role in fighting HIV from the initial binding and fusion of HIV into immune cells
However, despite industry advances in treatment and prevention, HIV continues to be marked by intense social stigma, rooted in fear and misconceptions that persist from the epidemic’s early days. Self-stigma is also prevalent and hinders individuals from getting tested, starting pre‑exposure prophylaxis (PrEP) (if they’re HIV negative), seeking the lifesaving treatments they need (if they’re HIV positive), and can lead to isolation and depression.3 While gone are the days when an HIV diagnosis necessitated taking so many pills that patients had to set multiple alarm clocks, self-stigma and concerns of external stigma still exist. They often arise when taking daily pills, causing fear of HIV status disclosure, stress and anxiety about staying adherent, and the constant reminder that the individual is living with HIV.3
But that paradigm is rapidly changing. Through research and development, there is potential for options that reduce the number of times maintenance medicines need to be taken to suppress HIV as well as reduce the number medicines taken over an individual’s lifetime. These steps can help lessen the impact of HIV stigma by allowing many people to have a choice in treatment options.
Where we are going
While longer acting regimens have transformed the HIV treatment landscape for many people living with the virus, our work to end the epidemic will not stop. Achieving an undetectable viral load should be the starting point for an HIV treatment. For individuals living with HIV, feeling like their life is not dictated by the disease is what the industry is working towards. Through direct engagement and collaboration with the HIV community – people who live with HIV, their providers and those who support them, along with people who want to prevent acquiring HIV – we know more is needed. Individuals with HIV who adhere to their ART regimens can successfully achieve undetectable levels of the virus in their blood and eliminate the risk of disease transmission; however, they must remain on treatment to maintain suppression of HIV.
These insights are leading to further, meaningful innovation, currently underway in the form of ‘ultra long-acting’ treatment and prevention options, along with at-home self-administration treatment options. In the coming years, the goal is for HIV medicines to be taken in intervals that allow at least three or four months between doses, as well as the ability to take them in the privacy of home as opposed to a health clinic. Beyond the potential to provide disease suppression on par with current regimens, many people living with HIV say this would also help reduce the emotional toll and reminder of their HIV status that can come from taking a daily treatment.
Having clinical trial designs focused on diversity is important.
Innovation will also extend beyond treatment duration and encompass the targets we attack to fight the HIV lifecycle in the human body. For more than 15 years, integrase strand transfer inhibitors (INSTIs) have served as the foundation of ART regimens in HIV treatment guidelines around the world and our present portfolio is built on them. While our research for next-generation long-acting regimens has INSTIs at their core, research will also look at other novel mechanisms of action that can attack various targets across the HIV replication cycle.
For example, broadly neutralising antibodies (bNAbs), capsid inhibitors and maturation inhibitors all might play a role in fighting HIV from the initial binding and fusion of HIV into immune cells, to where it integrates into the cell, out to its assembly and maturation.
We know that developing more treatment and prevention options are essential to tackling the still pervasive HIV epidemic. But that in itself is not enough when considering the spectrum of populations that require these medicines. Having a strong focus on recruiting diverse clinical trial participants along with additional implementation science studies can help industry bridge the gap between research findings and delivery of these different options. Having clinical trial designs focused on diversity – including a deep understanding of the demographics where HIV has the greatest impact – is critical to reduce biases, promote social justice and health equity and produce more innovative science. Most importantly, this will allow us to better identify what works best, why it works, and how findings can continuously be applied to improve the lives of anyone with HIV, regardless of race, ethnicity and socioeconomic status, among other variables.
As we move through the decade, we anticipate driving a fundamental shift in how HIV is treated and prevented with ultra long-acting options
Finally, advances in therapies that reduce viral load and ease the treatment burden for patients are exciting, but they will not distract us from our end game – a cure for HIV. What was once seen as a hopeful dream decades ago, now promises to be a realistic opportunity for people living with HIV. The core of our cure strategy is focused on identifying dormant HIV that may be hiding in human cells undetected by the immune system or HIV treatment. Once identified, the idea is to drive this virus out of hiding with medication so that it can be eliminated and then harness the body’s own immune responses against rebounding virus. As the only company completely focused on HIV, we are well aware that every resource we invest in researching a cure for HIV is an investment in putting our company out of business. It’s emblematic of our commitment to be here until HIV and AIDS are not.
The decade ahead
As we move through the decade, we anticipate driving a fundamental shift in how HIV is treated and prevented with ultra long-acting options. This will signal a major market shift from the past, which has been dominated by daily regimens, to a landscape that offers a variety of longer acting options that can be taken less frequently and delivered in new ways. We view this shift as being key to meeting the evolving needs of people living with HIV and those who may have reasons for HIV prevention, who expect new options to make HIV a smaller part of their lives.
As we advance these ultra long-acting options through clinical research and regulatory approval, we will not lose sight of our promise to leave no person living with HIV behind.
About the author
Sherene Min, MD, MPH, is Vice President of Global Clinical Development at ViiV Healthcare, a role she assumed in October 2019. As a physician scientist with knowledge and experience in translational medicine and late-stage drug development, Sherene has a proven record in drug development including successful regulatory interactions with US and international agencies. With therapeutic expertise in HIV, hepatology and rare diseases, Sherene has additional expertise in clinical pharmacology and drug safety.
Sherene has worked in the healthcare sector for more than 20 years, including in several leadership roles at GSK. Prior to joining ViiV, she served at an industry position with Roivant Sciences as Vice President of Clinical Research, where she managed the Rare Diseases portfolio.
Sherene completed her undergraduate work at UNC at Chapel Hill and earned her medical doctorate from the UNC School of Medicine in 1997. She completed an internal medicine residency at Washington University School of Medicine in St Louis. Additionally, she completed an infectious diseases fellowship at UNC School of Medicine while concurrently earning a Masters in Public Health from the UNC School of Public Health, completing her fellowship and earning her MPH in 2003.
References
1. World Health Organization. The Global Health Observatory. HIV. [Internet] 2023. [cited 2024Jan] Available from: https://www.who.int/data/gho/data/themes/hiv-aids
2. Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295-e307.
3. The Positive Perspectives Survey Report. [Internet] 2017. [cited 2024Jan] Available from: https://edgesuite.gskstatic.com/Viiv/viivhealthcare/pdf_files/master/main/positive-perspectives-survey-report-finalcompressed.pdf.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.